Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Double homeobox 4 like 14 (DUX4L14) is a pseudogene that shares sequence similarity with DUX4, a transcription factor implicated in embryonic development and diseases such as facioscapulohumeral muscular dystrophy (FSHD)[2]. Unlike DUX4, DUX4L14 does not encode a protein and has no established physiological, pathological, or therapeutic relevance. Its nomenclature and sequence may lead to confusion with DUX4, a gene of medical and biological importance, but DUX4L14 itself is not considered a therapeutic target and is not functionally characterized in the context of human disease, signaling, or pharmacology[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Double homeobox 4 like 14 (pseudogene) (DUX4L14).